The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
Abstract
CONTEXT: The risk of bacterial infection is increased in patients treated with drugs that inhibit tumor necrosis factor alpha (TNF-alpha). Little is known about the reactivation of latent viral infections during treatment with TNF-alpha inhibitors. OBJECTIVE: To investigate whether TNF-alpha inhibitors together as a class, or separately as either monoclonal anti-TNF-alpha antibodies (adalimumab, infliximab) or a fusion protein (etanercept), are related to higher rates of herpes zoster in patients with rheumatoid arthritis. DESIGN, SETTING, AND PATIENTS: Patients were enrolled in the German biologics register RABBIT, a prospective cohort, between May 2001 and December 2006 at the initiation of treatment with infliximab, etanercept, adalimumab, or anakinra, or when they changed conventional disease-modifying antirheumatic drug (DMARD). Treatment, clinical status, and adverse events were assessed by rheumatologists at fixed points during follow-up. MAIN OUTCOME MEASURES: Hazard ratio (HR) of herpes zoster episodes following anti-TNF-alpha treatment. Study aims were to detect a clinically significant difference (HR, 2.0) between TNF-alpha inhibitors as a class compared with DMARDs and to detect an HR of at least 2.5 for each of 2 types of TNF-alpha inhibitors, the monoclonal antibodies or the fusion protein, compared with conventional DMARDs. RESULTS: Among 5040 patients receiving TNF-alpha inhibitors or conventional DMARDs, 86 episodes of herpes zoster occurred in 82 patients. Thirty-nine occurrences could be attributed to treatment with anti-TNF-alpha antibodies, 23 to etanercept, and 24 to conventional DMARDs. The crude incidence rate per 1000 patient-years was 11.1 (95% confidence interval [CI], 7.9-15.1) for the monoclonal antibodies, 8.9 (95% CI, 5.6-13.3) for etanercept, and 5.6 (95% CI, 3.6-8.3) for conventional DMARDs. Adjusted for age, rheumatoid arthritis severity, and glucocorticoid use, a significantly increased risk was observed for treatment with the monoclonal antibodies (HR, 1.82 [95% CI, 1.05-3.15]), although this risk was lower than the threshold for clinical significance. No significant associations were found for etanercept use (HR, 1.36 [95% CI, 0.73-2.55]) or for anti-TNF-alpha treatment (HR, 1.63 [95% CI, 0.97-2.74]) as a class. CONCLUSION: Treatment with monoclonal anti-TNF-alpha antibodies may be associated with increased risk of herpes zoster, but this requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
Arvin, A. M. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.3.361 · Cited by 1,162
INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Self-citationPostherpetic Neuralgia — Pathogenesis, Treatment, and Prevention
Kost, R. G., & Straus, S. E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350107 · Cited by 641
What does epidemiology tell us about risk factors for herpes zoster?
Thomas, S. L., & Hall, A. J. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00857-0 · Cited by 561
Collett, D. (1994) · Modelling Survival Data in Medical Research · doi:10.1007/978-1-4899-3115-3_3 · Cited by 518
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Furst, D., Weisman, M. H., St.Clair, E. W., Keenan, G. F., van der Heijde, D., Marsters, P. A., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20159 · Cited by 514
Furst, D. E., Schiff, M. H., Fleischmann, R., Strand, V., Birbara, C. A., Compagnone, D., Fischkoff, S. A., & Chartash, E. (2003) · PubMed · Cited by 495
Curtis, J. R., Patkar, N., Xie, A., Martin, C., Allison, J. J., Saag, M., Shatin, D., & Saag, K. G. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22504 · Cited by 398
Askling, J., Fored, C. M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062760 · Cited by 334
Dixon, W. G., Symmons, D. P. M., Lunt, M., Watson, K. D., Hyrich, K. L., & Silman, A. J. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22808 · Cited by 307
Smitten, A. L., Choi, H. K., Hochberg, M. C., Suissa, S., Simon, T. A., Testa, M. A., & Chan, K. A. (2007) · Arthritis Care & Research · doi:10.1002/art.23112 · Cited by 281
Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction
Wallis, R. S., Broder, M., Wong, J., & Beenhouwer, D. (2004) · Clinical Infectious Diseases · doi:10.1086/424455 · Cited by 219
Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel Disease
Gupta, G., Lautenbach, E., & Lewis, J. D. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.09.019 · Cited by 208
Listing, J., Strangfeld, A., Rau, R., Kekow, J., Gromnica-Ihle, E., Klopsch, T., Demary, W., Burmester, G.-R., & Zink, A. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1933 · Cited by 181
Self-citationTreatment continuation in patients receiving biological agents or conventional DMARD therapy
Zink, A., Listing, J., Kary, S., Ramlau, P., Stoyanova‐Scholz, M., Babinsky, K., von Hinüber, U., Gromnica‐Ihle, E., Wassenberg, S., Antoni, C., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031476 · Cited by 164
Wallis, R. S., & Ehlers, S. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.01.009 · Cited by 160
Wolfe, F., Michaud, K. D., & Chakravarty, E. F. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel328 · Cited by 153
Lautenschläger, J., Mau, W., Kohlmann, T., Raspe, H. H., Struve, F., Brückle, W., & Zeidler, H. K. (1997) · Zeitschrift für Rheumatologie · doi:10.1007/s003930050030 · Cited by 148
Moreland, L. W., Weinblatt, M. E., Keystone, E. C., Kremer, J. M., Martin, R. W., Schiff, M. H., Whitmore, J. B., & White, B. (2006) · PubMed · Cited by 117
Bacterial and opportunistic infections during anti-TNF therapy
Strangfeld, A., & Listing, J. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.08.010 · Cited by 115
Self-citationVaricella vaccination in a child with acute lymphoblastic leukaemia
Schrauder, A., Henke‐Gendo, C., Seidemann, K., Sasse, M., Cario, G., Moericke, A., Schrappe, M., Heim, A., & Wessel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60567-4 · Cited by 72
WOODWORTH, T. G., Furst, D. E., Strand, V., et al. (2001) · PubMed · Cited by 34
D’Agostino (1998) · doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b
Cited by
Scott, D. L., Wolfe, F., & Huizinga, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60826-4 · Cited by 3,013
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit684 · Cited by 1,613
Gabriel, S. E., & Michaud, K. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2669 · Cited by 891
Dougados, M., & Baeten, D. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60071-8 · Cited by 780
Ramiro, S., Gaujoux-Viala, C., Nam, J. L., Smolen, J. S., Buch, M., Gossec, L., van der Heijde, D., Winthrop, K., & Landewé, R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204575 · Cited by 701
Metadata
- Authors
- Strangfeld, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-02-18
- Volume
- 301
- Issue
- 7
- Pages
- 737
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2075994714
- Cited by
- 542
- References
- 31
- FWCI
- 40.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.